Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
151 USD | +4.41% | +1.84% | -3.49% |
04:39pm | Johnson & Johnson Seeks EU Approval for Ulcerative Colitis, Crohn’s Disease Drug | MT |
04:17pm | Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.49% | 348B | |
+32.94% | 704B | |
+28.59% | 577B | |
+18.52% | 327B | |
+5.02% | 288B | |
+14.70% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.94% | 147B | |
-7.33% | 145B |
- Stock Market
- Equities
- JNJ Stock
- News Johnson & Johnson
- Johnson & Johnson Unit Janssen Says Initial Data From Phase 2 Trial of Balversa Shows Responses for Some Tumors